113 related articles for article (PubMed ID: 36177820)
1. Use of teduglutide for short bowel syndrome and Crohn's disease in a patient treated with ustekinumab and vedolizumab dual biologic therapy.
Martí Romero L; Peño Muñoz L; Martínez Escapa V; Hinojosa Del Val J
Rev Esp Enferm Dig; 2023 Jun; 115(6):331-332. PubMed ID: 36177820
[TBL] [Abstract][Full Text] [Related]
2. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
Singh S; Murad MH; Fumery M; Sedano R; Jairath V; Panaccione R; Sandborn WJ; Ma C
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):1002-1014. PubMed ID: 34688373
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of ustekinumab or vedolizumab after one year in 130 patients with anti-TNF-refractory Crohn's disease.
Townsend T; Razanskaite V; Dodd S; Storey D; Michail S; Morgan J; Davies M; Penman D; Watters C; Swaminathan M; Sabine J; Chapman A; Smith PJ; Flanagan PK; Reilly I; Bodger K; Subramanian S
Aliment Pharmacol Ther; 2020 Oct; 52(8):1341-1352. PubMed ID: 32955122
[TBL] [Abstract][Full Text] [Related]
4. Comparison of surgery rates in biologic-naïve patients with Crohn's disease treated with vedolizumab or ustekinumab: findings from SOJOURN.
Vu M; Ghosh S; Umashankar K; Weber L; Landis C; Candela N; Chastek B
BMC Gastroenterol; 2023 Mar; 23(1):87. PubMed ID: 36966279
[TBL] [Abstract][Full Text] [Related]
5. Systemic lupus erythematosus complicated by Crohn's disease with rectovaginal fistula.
Yeh H; Wu RC; Tsai WS; Kuo CJ; Su MY; Chiu CT; Le PH
BMC Gastroenterol; 2021 May; 21(1):206. PubMed ID: 33964869
[TBL] [Abstract][Full Text] [Related]
6. Dual biologic therapy with Vedolizumab and Ustekinumab for refractory Crohn's disease in children.
Howard G; Weiner D; Bar-Or I; Levine A
Eur J Gastroenterol Hepatol; 2022 Apr; 34(4):372-374. PubMed ID: 34034281
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn's disease.
Yang E; Panaccione N; Whitmire N; Dulai PS; Vande Casteele N; Singh S; Boland BS; Collins A; Sandborn WJ; Panaccione R; Battat R
Aliment Pharmacol Ther; 2020 Jun; 51(11):1031-1038. PubMed ID: 32329532
[TBL] [Abstract][Full Text] [Related]
8. Comparison of short- and long-term effectiveness between ustekinumab and vedolizumab in patients with Crohn's disease refractory to anti-tumour necrosis factor therapy.
Manlay L; Boschetti G; Pereira B; Flourié B; Dapoigny M; Reymond M; Sollelis E; Gay C; Boube M; Buisson A; Nancey S
Aliment Pharmacol Ther; 2021 Jun; 53(12):1289-1299. PubMed ID: 33909920
[TBL] [Abstract][Full Text] [Related]
9. Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn's Disease Patients.
Gebeyehu GG; Fiske J; Liu E; Limdi JK; Broglio G; Selinger C; Razsanskaite V; Smith PJ; Flanagan PK; Subramanian S
Dig Dis Sci; 2023 May; 68(5):1983-1994. PubMed ID: 36436155
[TBL] [Abstract][Full Text] [Related]
10. Identification of the Most Effective Position for Ustekinumab in Treatment Algorithms for Crohn's Disease.
Scott FI; Hans AK; Gerich ME; Fennimore B; Mamtani R; Vajravelu RK; Lewis JD
Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2082-2092.e10. PubMed ID: 32801006
[TBL] [Abstract][Full Text] [Related]
11. [Perianal fistulas in Crohn's disease: treatment results at an interdisciplinary unit].
Iesalnieks I; Glass H; Kilger A; Ott C; Klebl F; Agha A; Schlitt HJ; Strauch U
Chirurg; 2009 Jun; 80(6):549-58. PubMed ID: 19387561
[TBL] [Abstract][Full Text] [Related]
12. Biologics and 30-Day Postoperative Complications After Abdominal Operations for Crohn's Disease: Are There Differences in the Safety Profiles?
Lightner AL; McKenna NP; Alsughayer A; Harmsen WS; Taparra K; Parker ME; Raffals LE; Loftus EV
Dis Colon Rectum; 2019 Nov; 62(11):1352-1362. PubMed ID: 31567927
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study.
Borren NZ; Tan W; Colizzo FP; Luther J; Garber JJ; Khalili H; van Der Woude CJ; Ananthakrishnan AN
J Crohns Colitis; 2020 Mar; 14(3):309-315. PubMed ID: 31504365
[TBL] [Abstract][Full Text] [Related]
14. Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn's disease patients with prior failure to anti-TNF treatment.
Biemans VBC; van der Woude CJ; Dijkstra G; van der Meulen-de Jong AE; Löwenberg M; de Boer NK; Oldenburg B; Srivastava N; Jansen JM; Bodelier AGL; West RL; de Vries AC; Haans JJL; de Jong D; Hoentjen F; Pierik MJ;
Aliment Pharmacol Ther; 2020 Jul; 52(1):123-134. PubMed ID: 32441396
[TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Biologics for Endoscopic Healing of the Ileum and Colon in Crohn's Disease.
Narula N; Wong ECL; Dulai PS; Marshall JK; Jairath V; Reinisch W
Am J Gastroenterol; 2022 Jul; 117(7):1106-1117. PubMed ID: 35435862
[TBL] [Abstract][Full Text] [Related]
16. Dual Biologic and Small Molecule Therapy for the Treatment of Refractory Pediatric Inflammatory Bowel Disease.
Dolinger MT; Spencer EA; Lai J; Dunkin D; Dubinsky MC
Inflamm Bowel Dis; 2021 Jul; 27(8):1210-1214. PubMed ID: 33125058
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Crohn's Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist.
Holko P; Kawalec P; Pilc A
Pharmacoeconomics; 2018 Jul; 36(7):853-865. PubMed ID: 29667146
[TBL] [Abstract][Full Text] [Related]
18. Ustekinumab is effective for perianal fistulising Crohn's disease: a real-world experience and systematic review with meta-analysis.
Godoy Brewer GM; Salem G; Afzal MA; Limketkai BN; Haq Z; Tajamal M; Melia J; Lazarev M; Selaru FM; Parian AM
BMJ Open Gastroenterol; 2021 Dec; 8(1):. PubMed ID: 34920992
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice.
Gisbert JP; Chaparro M
J Crohns Colitis; 2020 Jun; 14(5):694-709. PubMed ID: 31777929
[TBL] [Abstract][Full Text] [Related]
20. The outcome of Crohn's disease patients refractory to anti-TNF and either vedolizumab or ustekinumab.
Kassouri L; Amiot A; Kirchgesner J; Tréton X; Allez M; Bouhnik Y; Beaugerie L; Carbonnel F; Meyer A
Dig Liver Dis; 2020 Oct; 52(10):1148-1155. PubMed ID: 32828693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
